Abstract 42P
Patient-derived xenograft (PDX), a cancer stem cell (CSC)-derived in vivo model, is an accepted model of choice for preclinical and translational research due to its proven predictive power. Patient-derived cancer organoids (PDOs), also CSC-derived 3D culture of carcinoma with defined structures, harbor carcinoma’s multicellular components and mimics cancer lesion structures/heterogeneity, both genomicly and histopathologically. PDO was first described by Hans Clevers Lab and proven to be a predictive model for preclinical research, similar to PDX.
Resources from the same session
The exosomes transfer the acquired resistance of MCF-7 breast cancer cells to rapamycin and tamoxifen
Presenter: Alexander Scherbakov
Session: Poster Display & Cocktail
Resources:
Abstract
The CellMiner and CellMinerCDB web-applications as a base for pharmacogenomics
Presenter: William Reinhold
Session: Poster Display & Cocktail
Resources:
Abstract
The application of radiomics-based machine learning in the differential diagnosis between atypical low-grade astrocytoma and anaplastic astrocytoma
Presenter: Manni Wang
Session: Poster Display & Cocktail
Resources:
Abstract
Targeting leukemic stem cells using humanized chimeric immunotoxin
Presenter: Madhumathi Jayaprakasam
Session: Poster Display & Cocktail
Resources:
Abstract
Proteomics plus RNA-seq in advanced melanoma samples treated with anti-PD1 immunotherapy unravel resistance mechanisms
Presenter: Guillermo Prado
Session: Poster Display & Cocktail
Resources:
Abstract
Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
Presenter: Eric Angevin
Session: Poster Display & Cocktail
Resources:
Abstract
Pharmacogenomics of docetaxel response in prostate cancer: A precision medicine initiative
Presenter: Abhinav Grover
Session: Poster Display & Cocktail
Resources:
Abstract
OX401, a new generation of PARP-interfering drug for cancer treatment
Presenter: Wael Jdey
Session: Poster Display & Cocktail
Resources:
Abstract
Novel ERα degrader, 3,20(R)-dihydroxy-19-norpregnatriene, inhibits MCF-7 cell growth through p21/CDK2/CDK4 pathway
Presenter: Alexander Scherbakov
Session: Poster Display & Cocktail
Resources:
Abstract
L1CAM as a candidate therapeutic target in small-cell neuroendocrine prostate cancer
Presenter: Alexandra Corella
Session: Poster Display & Cocktail
Resources:
Abstract